問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

List

1336Cases

2025-03-01 - 2027-08-31

Phase II

Active
A Phase 2, multicenter, multiple-dose, monotherapy study to evaluate the safety of OBI-858 in participants with moderate to severe glabellar lines.

  • Condition/Disease

    Moderate to severe glabellar lines

  • Test Drug

    OBI-858

Participate Sites
5Sites

Recruiting5Sites

2005-11-01 - 2007-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2020-07-20 - 2029-05-26

Phase III

Active
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

  • Condition/Disease

    Myelofibrosis (MF)

  • Test Drug

    Navitoclax

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

2023-12-01 - 2027-03-31

Phase II

Active
A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab and to Evaluate Safety and Efficacy of ABBV-400 in Combination With Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer

  • Condition/Disease

    Unresectable Metastatic Colorectal Cancer

  • Test Drug

    N/A N/A N/A N/A N/A

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2031-01-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-11-01 - 2029-08-31

Phase III

Active
AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    N/A

Participate Sites
10Sites

Recruiting10Sites

2016-03-01 - 2023-10-31

Phase III

Active
A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)

  • Condition/Disease

    Moderately to Severely Active Rheumatoid Arthritis

  • Test Drug

    ABT-494

Participate Sites
10Sites

Terminated8Sites

賴建志
Taipei Veterans General Hospital

Division of Rheumatology

郭昶甫
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2018-06-26 - 2030-12-31

Phase II

Active
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion

  • Condition/Disease

    Chronic Lymphocytic Leukemia

  • Test Drug

    Venetoclax

Participate Sites
8Sites

Recruiting7Sites

2025-06-01 - 2032-04-30

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2026-01-01 - 2031-07-31

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

1 20 21 22 23 24 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB